Prospective study of proton beam radiation therapy for adjuvant and definitive treatment of thymoma and thymic carcinoma: Early response and toxicity assessment

Prospective study of proton‐beam radiation therapy for limited‐stage small cell lung cancer

“…Our dosimetric figures (in both the PBT and IMRT groups), showing low radiation doses to the heart, lungs, and esophagus, are similar to those of numerous other publications on the use of PBT in the treatment of locally advanced NSCLC and other intrathoracic neoplasms . Most notably, PBT decreased the lung volume receiving low doses and the mean dose but not the lung V 20 value.…”

“…Our dosimetric figures (in both the PBT and IMRT groups), showing low radiation doses to the heart, lungs, and esophagus, are similar to those of numerous other publications on the use of PBT in the treatment of locally advanced NSCLC and other intrathoracic neoplasms. 4,[14][15][16][17][18][19] Most notably, PBT decreased the lung volume receiving low doses and the mean dose but not the lung V 20 value. This could be explained not only by the decreased side scatter and unique Bragg peak associated with PBT but also by the fact that the vast majority of the patients Abbreviations: IMRT, intensity-modulated radiotherapy; V n , volume receiving at least n grays.…”

Postoperative Radiation Therapy Is Associated with Longer Overall Survival in Completely Resected Stage II and III Thymoma—An Analysis of the International Thymic Malignancies Interest Group Retrospective Database

“…Early data from a prospective study at the University of Pennsylvania appears very promising with low esophagitis (7%) and pneumonitis (4%) rates. 28 It should be noted that PORT to the tumor bed, typically in the mediastinum, is assumed not to affect the risk of pleural recurrences. As previously described pleural recurrences are the most common site of failure in patients treated with surgical resection + PORT.…”

The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

“…The dosimetric rationale for proton therapy for MPM is compelling, and proton therapy has been reported to optimally preserve quality of life 27 while minimizing toxicity or resulting in improved outcomes in prospective studies and large series for adjuvant, 28 definitive, 26,29,30 or repeat 31 therapy for locally advanced NSCLC, SCLC, 32 and thymic malignancies 33 ; however, its use for MPM has to date been limited to small institutional series. Investigators from the M. D. Anderson Cancer Center compared PBS with IMRT plans for seven patients with lung-intact MPM, four of whom had been treated with PBS and three of whom had been treated with IMRT.…”